Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. - Wikidata - awgldk - TriplyDB

Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.

Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.

http://www.wikidata.org/entity/Q35205410

about

Targeting hypoxic response for cancer therapy Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer Omentum and bone marrow: how adipocyte-rich organs create tumour microenvironments conducive for metastatic progression Pooling and Analysis of Published in Vitro Data: A Proof of Concept Study for the Grouping of Nanoparticles.Targeting the tumour microenvironment in ovarian cancer FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression.Platelet Derived Growth Factor BB: A "Must-have" Therapeutic Target "Redivivus" in Ovarian Cancer.Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay The role of Notch signalling in ovarian angiogenesis.Ovarian cancer stem cells: still an elusive entity?Dual roles of protein tyrosine phosphatase kappa in coordinating angiogenesis induced by pro-angiogenic factors.Targeting tumor vasculature: expanding the potential of DNA cancer vaccines.Prediction of therapy response in ovarian cancer: Where are we now?Effect of Guibi-Tang, a Traditional Herbal Formula, on Retinal Neovascularization in a Mouse Model of Proliferative Retinopathy.Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance.Overexpression of Rab11-FIP2 in colorectal cancer cells promotes tumor migration and angiogenesis through increasing secretion of PAI-1.Role of tumor microenvironment in ovarian cancer pathobiology.The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance.Role of tumor microenvironment in the pathobiology of ovarian cancer: Insights and therapeutic opportunities

P2860

Q26767351-C9B97666-0E61-49E5-B8AF-C3CE9702DEFC Q26780387-4F9BFD4F-B2BB-490A-AF6D-4EA4E4B903C1 Q28076686-DCF4A539-1BB2-413D-A5B8-2890210BCED1 Q31018385-05694F22-31AD-4D9F-94A9-2FBFD1359FFA Q36626921-DE247C62-1E0B-446A-9B3E-0C1C70DE292D Q36867341-9D8B3920-9C73-439B-8D36-C7DB409CFD4A Q36983860-0DCE0901-DB60-40FE-B7CD-AD5FE8B9A4F1 Q37159783-CDD890E8-0714-4B8C-8CFB-273977DD8538 Q37570010-FECFB45F-8FAD-40D1-B8D6-5F4743EC5C22 Q37631567-1D49B1CF-73F6-4AE7-A62D-04074664A9A7 Q37694018-2A06DEF7-942E-4351-A934-3EA4681E4972 Q37713683-F8A61B17-DA41-4309-8223-22E66EAB0B20 Q37718673-90FD4D5F-89C6-47B3-A349-E3955EE8DD11 Q38565385-772F2D5C-F361-48A1-AE30-4C247D909073 Q39263260-A59C0A3C-2C4D-4959-98C0-3F0056CC48F2 Q41989268-E9361869-6CCA-4DD4-A795-1A5AB70C707F Q47282030-B72078E8-0611-4D9A-A97B-1865A160CB24 Q52655258-D35FB8E3-371A-4DF0-B905-D5C597580B6B Q55078149-21735150-6519-4ECF-A6E0-5D4AB919C375 Q55101661-0E893F22-2E88-4822-B98C-BFAFFB6E4934 Q58724750-ABB9BB4B-6C6E-463F-8F25-286BDBC32A08

P2860

Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.

http://www.wikidata.org/entity/Q35205410

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.

@ast

Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.

@en

type

label

Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.

@ast

Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.

@en

prefLabel

Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.

@ast

Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.

@en

P1433

Q35205410-D0BBCD2E-1698-483C-9BB8-788965A5BAF0

P1476

Q35205410-AC5CD124-B091-4DC8-A240-34A74E4238D0

P2093

Q35205410-822FE58C-1501-44F9-9EDA-FFF3C56D2DB8

Q35205410-B347A050-2B5B-4A70-9362-8F3B547601D9

Q35205410-C18CD6B1-283F-4DFD-A118-C487969D37AB

Q35205410-C2871760-8CFE-4356-B2A3-C3BF7318F03A

P2860

Q35205410-01D261D3-1424-4CAC-9EB0-54FEEDE9B884

Q35205410-05ACB7CE-BBC0-40B7-8F69-CCE1A84EF2AE

Q35205410-079E24F2-7D2D-4C30-9514-ACADFB7EFFEE

Q35205410-0A98FAB6-973A-479E-8A5E-323A344D7166

Q35205410-0DF846C5-0634-4F88-AA52-DFB714D78FA7

Q35205410-0EFB6E51-8C42-4D8E-B064-5645A1E33CA7

Q35205410-0F5E939B-2B07-4CB7-97B3-3E9E0273DD4F

Q35205410-12505833-5826-4399-9A61-E583D9567F11

Q35205410-13895DCA-25D0-49D6-A6E0-4EB8E704C10B

Q35205410-15416C74-86ED-4119-93DB-003DCAED3F09

P2888

Q35205410-0BB32437-A4A6-4064-97A0-B10614A0930B

P304

Q35205410-D589D23D-3E57-4138-9EF2-CD48C3474086

P31

Q35205410-6ABCDC1F-BD30-45E8-A06B-00DA561B4BC3

P356

Q35205410-BD7BCA6E-8A0D-43A8-963C-89B570B37A93

P433

Q35205410-0AD6ABD1-091C-4227-AEAB-DC46905B7A6B

P478

Q35205410-78B1B2DE-C5EA-45A5-941B-96BB39E6DC9A

P50

Q35205410-97CB7C84-C947-4E7D-8B02-B13C5900E834

Q35205410-BA1C5D82-6BB9-4ABE-81FA-9F654B366791

P577

Q35205410-CB5F3306-08A9-40C0-9519-7F5F4348F162

P5875

Q35205410-6872FA32-D89A-489A-99AE-D37B0E3E978C

P698

Q35205410-772B9A97-1FE2-406C-B7A8-0606834AF133

P921

Q35205410-87FA093F-5FC6-473F-9181-105EA55B83D0

P932

Q35205410-CD7F6547-0E8E-450F-9FAA-517AF5277532

P356

S10555-014-9538-9

P1433

Cancer and Metastasis Reviews

P1476

Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches

@en

P2093

Anil K Sood

http://www.w3.org/2001/XMLSchema#string

Min Soon Cho

http://www.w3.org/2001/XMLSchema#string

Robert L Coleman

http://www.w3.org/2001/XMLSchema#string

Sunila Pradeep

http://www.w3.org/2001/XMLSchema#string

P2860

Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage

Cellular signaling by fibroblast growth factor receptors

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product

Src family kinases in tumor progression and metastasis

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

Synaptojanin-2 binding protein stabilizes the Notch ligands DLL1 and DLL4 and inhibits sprouting angiogenesis

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels

P2888

s10555-014-9538-9

P304

19-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10555-014-9538-9

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P50

Guillermo Armaiz-Pena

P577

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270222149

http://www.w3.org/2001/XMLSchema#string

P698

25544368

http://www.w3.org/2001/XMLSchema#string

P921

P932

4369424

http://www.w3.org/2001/XMLSchema#string